Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuwei Kushen is a Traditional Chinese Medicine (TCM) formulation developed by Beijing Zhonghui Pharmaceutical for the treatment of ulcerative colitis. It is typically administered as enteric-coated capsules to ensure targeted delivery to the intestinal tract. The formulation is composed of five primary herbal ingredients: *Sophora flavescens* (Kushen), *Sanguisorba officinalis* (Di Yu), *Indigo naturalis* (Qing Dai), *Bletilla striata* (Bai Ji), and *Glycyrrhiza uralensis* (Gan Cao). Its mechanism of action involves multi-target anti-inflammatory and immunomodulatory effects, including the inhibition of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1 beta, as well as the regulation of the NF-kappaB signaling pathway. Additionally, it promotes the healing of the intestinal mucosa and helps restore the balance of intestinal flora. It is specifically indicated for patients presenting with the damp-heat syndrome of the large intestine in TCM clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wuwei Kushen.